Please use this identifier to cite or link to this item:
http://hdl.handle.net/11455/52013
DC Field | Value | Language |
---|---|---|
dc.contributor | 黃青真 | zh_TW |
dc.contributor | Ching-Jang Huang | en_US |
dc.contributor | 唐烽堯 | zh_TW |
dc.contributor | Feng-Yao Tang | en_US |
dc.contributor.advisor | 胡淼琳 | zh_TW |
dc.contributor.advisor | Miao-Lin Hu | en_US |
dc.contributor.author | Lu, Yi-Hsuan | en_US |
dc.contributor.author | 盧怡璇 | zh_TW |
dc.contributor.other | 中興大學 | zh_TW |
dc.date | 2010 | zh_TW |
dc.date.accessioned | 2014-06-06T08:55:30Z | - |
dc.date.available | 2014-06-06T08:55:30Z | - |
dc.identifier.citation | 衛生署2007年統計資料。 顏宇彤。2005。茄紅素在活體內及活體外對非雄性激素依賴型人類前列腺癌細胞的生長抑制效力。國立中興大學食品科學系碩士論文。台中。台灣。 呂雅苓。2008。茄紅素可促進PPARγ-LXRα-ABCA1之途徑而抑制男性荷爾蒙非依賴型前列腺癌細胞之生長。國立中興大學食品暨應用生物科技學系碩士論文。台中。台灣。 Attie, A.D., 2007. ABCA1: at the nexus of cholesterol, HDL and atherosclerosis. Trends Biochem Sci 32, 172-179. Bertram, J., Pung, A., Churley, M., Kappock IV, T., Wilkins, L. and Cooney, R., 1991. Diverse carotenoids protect against chemically induced neoplastic transformation. Carcinogenesis 12, 671. Blaschke, F., Leppanen, O., Takata, Y., Caglayan, E., Liu, J., Fishbein, M.C., Kappert, K., Nakayama, K.I., Collins, A.R., Fleck, E., Hsueh, W.A., Law, R.E. and Bruemmer, D., 2004. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res 95, e110-123. Campbell, J.K., Stroud, C.K., Nakamura, M.T., Lila, M.A. and Erdman, J.W., Jr., 2006. Serum testosterone is reduced following short-term phytofluene, lycopene, or tomato powder consumption in F344 rats. J Nutr 136, 2813-2819. Campbell, S.E., Stone, W.L., Whaley, S.G., Qui, M. and Krishnan, K., 2003. Gamma (gamma) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (gamma) expression in SW 480 human colon cancer cell lines. BMC Cancer 3, 25. Attie, A.D., 2007. ABCA1: at the nexus of cholesterol, HDL and atherosclerosis. Trends Biochem Sci 32, 172-179. Bertram, J., Pung, A., Churley, M., Kappock IV, T., Wilkins, L. and Cooney, R., 1991. Diverse carotenoids protect against chemically induced neoplastic transformation. Carcinogenesis 12, 671. Blaschke, F., Leppanen, O., Takata, Y., Caglayan, E., Liu, J., Fishbein, M.C., Kappert, K., Nakayama, K.I., Collins, A.R., Fleck, E., Hsueh, W.A., Law, R.E. and Bruemmer, D., 2004. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res 95, e110-123. Campbell, J.K., Stroud, C.K., Nakamura, M.T., Lila, M.A. and Erdman, J.W., Jr., 2006. Serum testosterone is reduced following short-term phytofluene, lycopene, or tomato powder consumption in F344 rats. J Nutr 136, 2813-2819. Campbell, S.E., Stone, W.L., Whaley, S.G., Qui, M. and Krishnan, K., 2003. Gamma (gamma) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (gamma) expression in SW 480 human colon cancer cell lines. BMC Cancer 3, 25. Castrillo, A. and Tontonoz, P., 2004. PPARs in atherosclerosis: the clot thickens. Journal of Clinical Investigation 114, 1538. Chan, J.M., Gann, P.H. and Giovannucci, E.L., 2005. Role of diet in prostate cancer development and progression. J Clin Oncol 23, 8152-8160. Chao, C.Y. and Huang, C.J., 2003. Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells. J Biomed Sci 10, 782-791. Chawla, A., Boisvert, W.A., Lee, C.H., Laffitte, B.A., Barak, Y., Joseph, S.B., Liao, D., Nagy, L., Edwards, P.A., Curtiss, L.K., Evans, R.M. and Tontonoz, P., 2001a. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7, 161-171. Chawla, A., Repa, J.J., Evans, R.M. and Mangelsdorf, D.J., 2001b. Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870. Chinetti, G., Lestavel, S., Bocher, V., Remaley, A.T., Neve, B., Torra, I.P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H.B., Fruchart, J.C., Clavey, V. and Staels, B., 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7, 53-58. Chuu, C.P., Hiipakka, R.A., Kokontis, J.M., Fukuchi, J., Chen, R.Y. and Liao, S., 2006. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res 66, 6482-6486. Chuu, C.P., Kokontis, J.M., Hiipakka, R.A. and Liao, S., 2007. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J Biomed Sci 14, 543-553. Clinton, S.K., 1998. Lycopene: chemistry, biology, and implications for human health and disease. Nutr Rev 56, 35-51. Costet, P., Luo, Y., Wang, N. and Tall, A.R., 2000. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 275, 28240-28245. Culig, Z., Steiner, H., Bartsch, G. and Hobisch, A., 2005. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95, 497-505. De Stefani, E., Mendilaharsu, M., Deneo-Pellegrini, H. and Ronco, A., 1997. Influence of dietary levels of fat, cholesterol, and calcium on colorectal cancer. Nutr Cancer 29, 83-89. Desvergne, B. and Wahli, W., 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20, 649-688. Ford, E.S., 2000. Variations in serum carotenoid concentrations among United States adults by ethnicity and sex. Ethn Dis 10, 208-217. Freeman, M.R. and Solomon, K.R., 2004. Cholesterol and prostate cancer. J Cell Biochem 91, 54-69. Fukuchi, J., Hiipakka, R.A., Kokontis, J.M., Hsu, S., Ko, A.L., Fitzgerald, M.L. and Liao, S., 2004a. Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells. Cancer Res 64, 7682-7685. Fukuchi, J., Kokontis, J.M., Hiipakka, R.A., Chuu, C.P. and Liao, S., 2004b. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res 64, 7686-7689. Gentili, C., Tutolo, G., Pianezzi, A., Cancedda, R. and Descalzi Cancedda, F., 2005. Cholesterol secretion and homeostasis in chondrocytes: a liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein A1 expression. Matrix Biol 24, 35-44. Giovannucci, E., Rimm, E.B., Liu, Y., Stampfer, M.J. and Willett, W.C., 2002. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 94, 391-398. Goldstein, J.L., DeBose-Boyd, R.A. and Brown, M.S., 2006. Protein sensors for membrane sterols. Cell 124, 35-46. Hager, M.H., Solomon, K.R. and Freeman, M.R., 2006. The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care 9, 379-385. Hantz, H.L., Young, L.F. and Martin, K.R., 2005. Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp Biol Med (Maywood) 230, 171-179. Heber, D. and Lu, Q.Y., 2002. Overview of mechanisms of action of lycopene. Exp Biol Med (Maywood) 227, 920-923. Hellerstedt, B.A. and Pienta, K.J., 2002. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52, 154-179. Horn-Ross, P.L., Morrow, M. and Ljung, B.M., 1997. Diet and the risk of salivary gland cancer. Am J Epidemiol 146, 171-176. Horoszewicz, J.S., Leong, S.S., Kawinski, E., Karr, J.P., Rosenthal, H., Chu, T.M., Mirand, E.A. and Murphy, G.P., 1983. LNCaP model of human prostatic carcinoma. Cancer Res 43, 1809-1818. Hsueh, W.A. and Law, R., 2003. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol 92, 3J-9J. Huang, C.S., Fan, Y.E., Lin, C.Y. and Hu, M.L., 2007. Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1. J Nutr Biochem 18, 449-456. Huang, C.S., Liao, J.W. and Hu, M.L., 2008. Lycopene inhibits experimental metastasis of human hepatoma SK-Hep-1 cells in athymic nude mice. J Nutr 138, 538-543. Huang, C.S., Shih, M.K., Chuang, C.H. and Hu, M.L., 2005. Lycopene inhibits cell migration and invasion and upregulates Nm23-H1 in a highly invasive hepatocarcinoma, SK-Hep-1 cells. J Nutr 135, 2119-2123. Hwang, E.S. and Lee, H.J., 2006. Inhibitory effects of lycopene on the adhesion, invasion, and migration of SK-Hep1 human hepatoma cells. Exp Biol Med (Maywood) 231, 322-327. Iannelli, P., Zarrilli, V., Varricchio, E., Tramontano, D. and Mancini, F.P., 2007. The dietary antioxidant resveratrol affects redox changes of PPARα activity. Nutrition, Metabolism and Cardiovascular Diseases 17, 247-256. Inoue, H., 2005. [Endogenous ligands for PPARs]. Nippon Rinsho 63, 578-583. Ivanov, N.I., Cowell, S.P., Brown, P., Rennie, P.S., Guns, E.S. and Cox, M.E., 2007. Lycopene differentially induces quiescence and apoptosis in androgen-responsive and -independent prostate cancer cell lines. Clin Nutr 26, 252-263. Janowski, B.A., Grogan, M.J., Jones, S.A., Wisely, G.B., Kliewer, S.A., Corey, E.J. and Mangelsdorf, D.J., 1999. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci U S A 96, 266-271. Jarvinen, R., Knekt, P., Hakulinen, T., Rissanen, H. and Heliovaara, M., 2001. Dietary fat, cholesterol and colorectal cancer in a prospective study. Br J Cancer 85, 357-361. Joseph, S.B., Castrillo, A., Laffitte, B.A., Mangelsdorf, D.J. and Tontonoz, P., 2003. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9, 213-219. Joseph, S.B., McKilligin, E., Pei, L., Watson, M.A., Collins, A.R., Laffitte, B.A., Chen, M., Noh, G., Goodman, J., Hagger, G.N., Tran, J., Tippin, T.K., Wang, X., Lusis, A.J., Hsueh, W.A., Law, R.E., Collins, J.L., Willson, T.M. and Tontonoz, P., 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 99, 7604-7609. Kanagaraj, P., Vijayababu, M.R., Ravisankar, B., Anbalagan, J., Aruldhas, M.M. and Arunakaran, J., 2007. Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells. J Cancer Res Clin Oncol 133, 351-359. Karas, M., Amir, H., Fishman, D., Danilenko, M., Segal, S., Nahum, A., Koifmann, A., Giat, Y., Levy, J. and Sharoni, Y., 2000. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 36, 101-111. Kast-Woelbern, H.R., Dana, S.L., Cesario, R.M., Sun, L., de Grandpre, L.Y., Brooks, M.E., Osburn, D.L., Reifel-Miller, A., Klausing, K. and Leibowitz, M.D., 2004. Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis. J Biol Chem 279, 23908-23915. Khachik, F., Carvalho, L., Bernstein, P.S., Muir, G.J., Zhao, D.Y. and Katz, N.B., 2002. Chemistry, distribution, and metabolism of tomato carotenoids and their impact on human health. Experimental Biology and Medicine 227, 845-851. King, T.J. and Bertram, J.S., 2005. Connexins as targets for cancer chemoprevention and chemotherapy. Biochim Biophys Acta 1719, 146-160. Kliewer, S.A., Lehmann, J.M. and Willson, T.M., 1999. Orphan nuclear receptors: shifting endocrinology into reverse. Science 284, 757-760. Knight, B.L., 2004. ATP-binding cassette transporter A1: regulation of cholesterol efflux. Biochem Soc Trans 32, 124-127. Laffitte, B.A., Repa, J.J., Joseph, S.B., Wilpitz, D.C., Kast, H.R., Mangelsdorf, D.J. and Tontonoz, P., 2001. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A 98, 507-512. Lecka-Czernik, B., Ackert-Bicknell, C., Adamo, M.L., Marmolejos, V., Churchill, G.A., Shockley, K.R., Reid, I.R., Grey, A. and Rosen, C.J., 2007. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148, 903-911. Lee, C.H. and Evans, R.M., 2002. Peroxisome proliferator-activated receptor-gamma in macrophage lipid homeostasis. Trends Endocrinol Metab 13, 331-335. Lehmann, J.M., Kliewer, S.A., Moore, L.B., Smith-Oliver, T.A., Oliver, B.B., Su, J.L., Sundseth, S.S., Winegar, D.A., Blanchard, D.E. and Spencer, T.A., 1997. Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway. Journal of Biological Chemistry 272, 3137. Levy, J., Bosin, E., Feldman, B., Giat, Y., Miinster, A., Danilenko, M. and Sharoni, Y., 1995. Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. Nutr Cancer 24, 257-266. Li, A.C. and Glass, C.K., 2002. The macrophage foam cell as a target for therapeutic intervention. Nat Med 8, 1235-1242. Li, A.C. and Glass, C.K., 2004. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 45, 2161-2173. Limpens, J., Schroder, F.H., de Ridder, C.M., Bolder, C.A., Wildhagen, M.F., Obermuller-Jevic, U.C., Kramer, K. and van Weerden, W.M., 2006. Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J Nutr 136, 1287-1293. Liu, C., Lian, F., Smith, D.E., Russell, R.M. and Wang, X.D., 2003. Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res 63, 3138-3144. Livny, O., Kaplan, I., Reifen, R., Polak-Charcon, S., Madar, Z. and Schwartz, B., 2002. Lycopene inhibits proliferation and enhances gap-junction communication of KB-1 human oral tumor cells. J Nutr 132, 3754-3759. Mangels, A.R., Holden, J.M., Beecher, G.R., Forman, M.R. and Lanza, E., 1993. Carotenoid content of fruits and vegetables: an evaluation of analytic data. J Am Diet Assoc 93, 284-296. Matsuyama, M. and Yoshimura, R., 2008. Peroxisome Proliferator-Activated Receptor-gamma Is a Potent Target for Prevention and Treatment in Human Prostate and Testicular Cancer. PPAR Res 2008, 249849. Mayne, S.T., Cartmel, B., Silva, F., Kim, C.S., Fallon, B.G., Briskin, K., Zheng, T., Baum, M., Shor-Posner, G. and Goodwin, W.J., Jr., 1999. Plasma lycopene concentrations in humans are determined by lycopene intake, plasma cholesterol concentrations and selected demographic factors. J Nutr 129, 849-854. Mein, J.R., Lian, F. and Wang, X.D., 2008. Biological activity of lycopene metabolites: implications for cancer prevention. Nutr Rev 66, 667-683. Miller, N.E., La Ville, A. and Crook, D., 1985. Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature 314, 109-111. Miller, N.J., Sampson, J., Candeias, L.P., Bramley, P.M. and Rice-Evans, C.A., 1996. Antioxidant activities of carotenes and xanthophylls. FEBS Lett 384, 240-242. Mueller, E., Smith, M., Sarraf, P., Kroll, T., Aiyer, A., Kaufman, D.S., Oh, W., Demetri, G., Figg, W.D., Zhou, X.P., Eng, C., Spiegelman, B.M. and Kantoff, P.W., 2000. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A 97, 10990-10995. Nagata, D., Yoshihiro, H., Nakanishi, M., Naruyama, H., Okada, S., Ando, R., Tozawa, K. and Kohri, K., 2008. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Cancer Detect Prev 32, 259-266. Nahum, A., Hirsch, K., Danilenko, M., Watts, C.K., Prall, O.W., Levy, J. and Sharoni, Y., 2001. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene 20, 3428-3436. Nahum, A., Zeller, L., Danilenko, M., Prall, O.W., Watts, C.K., Sutherland, R.L., Levy, J. and Sharoni, Y., 2006. Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. Eur J Nutr 45, 275-282. Nussey, S. and Whitehead, S.A., 2001. Endocrinology: an integrated approach. Taylor & Francis. Olefsky, J.M., 2001. Nuclear receptor minireview series. J Biol Chem 276, 36863-36864. Panzenboeck, U., Kratzer, I., Sovic, A., Wintersperger, A., Bernhart, E., Hammer, A., Malle, E. and Sattler, W., 2006. Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells. Int J Biochem Cell Biol 38, 1314-1329. Park, Y.O., Hwang, E.S. and Moon, T.W., 2005. The effect of lycopene on cell growth and oxidative DNA damage of Hep3B human hepatoma cells. Biofactors 23, 129-139. Peet, D.J., Turley, S.D., Ma, W., Janowski, B.A., Lobaccaro, J.M., Hammer, R.E. and Mangelsdorf, D.J., 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93, 693-704. Pham, H., Banerjee, T., Nalbandian, G.M. and Ziboh, V.A., 2003. Activation of peroxisome proliferator-activated receptor (PPAR)-gamma by 15S-hydroxyeicosatrienoic acid parallels growth suppression of androgen-dependent prostatic adenocarcinoma cells. Cancer Lett 189, 17-25. Pienta, K.J., Goodson, J.A. and Esper, P.S., 1996. Epidemiology of prostate cancer: molecular and environmental clues. Urology 48, 676-683. Rao, A. and Agarwal, S., 1999. Role of lycopene as antioxidant carotenoid in the prevention of chronic diseases: A review. Nutrition Research 19, 305-323. Repa, J.J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.M., Shimomura, I., Shan, B., Brown, M.S., Goldstein, J.L. and Mangelsdorf, D.J., 2000. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 14, 2819-2830. Ribaya-Mercado, J.D., Garmyn, M., Gilchrest, B.A. and Russell, R.M., 1995. Skin lycopene is destroyed preferentially over beta-carotene during ultraviolet irradiation in humans. J Nutr 125, 1854-1859. Salman, H., Bergman, M., Djaldetti, M. and Bessler, H., 2007. Lycopene affects proliferation and apoptosis of four malignant cell lines. Biomed Pharmacother 61, 366-369. Schultz, J.R., Tu, H., Luk, A., Repa, J.J., Medina, J.C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D.J., Lustig, K.D. and Shan, B., 2000. Role of LXRs in control of lipogenesis. Genes Dev 14, 2831-2838. Shay, N.F. and Banz, W.J., 2005. Regulation of gene transcription by botanicals: novel regulatory mechanisms. Annual Review of Nutrition 25, 297-315. Shimano, H., Horton, J.D., Shimomura, I., Hammer, R.E., Brown, M.S. and Goldstein, J.L., 1997. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 99, 846-854. Shimomura, I., Shimano, H., Horton, J.D., Goldstein, J.L. and Brown, M.S., 1997. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99, 838-845. Shulman, A.I. and Mangelsdorf, D.J., 2005. Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med 353, 604-615. Simpson, I., Rose, B. and Loewenstein, W.R., 1977. Size limit of molecules permeating the junctional membrane channels. Science 195, 294-296. Smith, M.R. and Kantoff, P.W., 2002. Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer. Invest New Drugs 20, 195-200. Song, C., Hiipakka, R.A. and Liao, S., 2001. Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis. Steroids 66, 473-479. Song, C. and Liao, S., 2001. Hypolipidemic effects of selective liver X receptor alpha agonists. Steroids 66, 673-681. Sporer, A., Brill, D.R. and Schaffner, C.P., 1982. Epoxycholesterols in secretions and tissues of normal, benign, and cancerous human prostate glands. Urology 20, 244-250. Stahl, W. and Sies, H., 1996. Lycopene: A Biologically Important Carotenoid for Humans? Archives of Biochemistry and Biophysics 336, 1-9. Stahl, W., von Laar, J., Martin, H.D., Emmerich, T. and Sies, H., 2000. Stimulation of gap junctional communication: comparison of acyclo-retinoic acid and lycopene. Arch Biochem Biophys 373, 271-274. Subbarayan, V., Sabichi, A.L., Kim, J., Llansa, N., Logothetis, C.J., Lippman, S.M. and Menter, D.G., 2004. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 13, 1710-1716. Swinnen, J.V., Van Veldhoven, P.P., Esquenet, M., Heyns, W. and Verhoeven, G., 1996. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 137, 4468-4474. Swyer, G.I.M., 1942. The cholesterol content of normal and enlarged prostates. Cancer Research 2, 372. Tang, L., Jin, T., Zeng, X. and Wang, J.S., 2005. Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in BALB/c nude mice. J Nutr 135, 287-290. Tanigawa, S., Fujii, M. and Hou, D.X., 2007. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. Free Radic Biol Med 42, 1690-1703. Tobin, K.A., Steineger, H.H., Alberti, S., Spydevold, O., Auwerx, J., Gustafsson, J.A. and Nebb, H.I., 2000. Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha. Mol Endocrinol 14, 741-752. Tontonoz, P. and Mangelsdorf, D.J., 2003. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17, 985-993. Tonucci, L., Holden, J., Beecher, G., Khachik, F., Davis, C. and Mulokozi, G., 1995. Carotenoid Content of Thermally Processed Tomato-Based Food Products. Journal of Agricultural and Food Chemistry 43, 579-586. Tsubakio-Yamamoto, K., Matsuura, F., Koseki, M., Oku, H., Sandoval, J.C., Inagaki, M., Nakatani, K., Nakaoka, H., Kawase, R., Yuasa-Kawase, M., Masuda, D., Ohama, T., Maeda, N., Nakagawa-Toyama, Y., Ishigami, M., Nishida, M., Kihara, S., Shimomura, I. and Yamashita, S., 2008. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun 375, 390-394. Tsubouchi, Y., Sano, H., Kawahito, Y., Mukai, S., Yamada, R., Kohno, M., Inoue, K., Hla, T. and Kondo, M., 2000. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 270, 400-405. Vinken, M., Vanhaecke, T., Papeleu, P., Snykers, S., Henkens, T. and Rogiers, V., 2006. Connexins and their channels in cell growth and cell death. Cell Signal 18, 592-600. Wang, A. and Zhang, L., 2007. [Effect of lycopene on proliferation and cell cycle of hormone refractory prostate cancer PC-3 cell line]. Wei Sheng Yan Jiu 36, 575-578. White, C.P., 1909. On the occurrence of crystals in tumours. The Journal of Pathology and Bacteriology 13. Wong, J., Quinn, C.M. and Brown, A.J., 2006. SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. Biochem J 400, 485-491. Yang, C., McDonald, J.G., Patel, A., Zhang, Y., Umetani, M., Xu, F., Westover, E.J., Covey, D.F., Mangelsdorf, D.J., Cohen, J.C. and Hobbs, H.H., 2006. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem 281, 27816-27826. Yoshikawa, T., Ide, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Matsuzaka, T., Yatoh, S., Kitamine, T., Okazaki, H., Tamura, Y., Sekiya, M., Takahashi, A., Hasty, A.H., Sato, R., Sone, H., Osuga, J., Ishibashi, S. and Yamada, N., 2003. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Mol Endocrinol 17, 1240-1254. Zhang, L.X., Acevedo, P., Guo, H. and Bertram, J.S., 1995. Upregulation of gap junctional communication and connexin43 gene expression by carotenoids in human dermal fibroblasts but not in human keratinocytes. Mol Carcinog 12, 50-58. | zh_TW |
dc.identifier.uri | http://hdl.handle.net/11455/52013 | - |
dc.description.abstract | Epidemiological studies suggest that elevated intake of lycopene is associated with a reduced risk of several types of cancer, such as prostate cancer and hepatoma. Several studies have demonstrated that the activation of peroxisome proliferator-activated receptor gamma (PPARγ) and liver X receptor alpha (LXRα) is related to reduce incidence of prostate cancer. However, the antiproliferative effects and mechanisms of lycopene on human prostate cancer are still unclear. Here, we employed androgen-dependent human prostate cancer cells (LNCaP) to examine whether lycopene inhibit the proliferation of prostate cancer via up-regulation of the expression of PPARγ and LXRα. Lycopene significantly inhibited the proliferation of LNCaP cells in a concentration -dependent manner (2.5-10 μM) for 24, 48 and 96 hr. Lycopene treatment significantly increased protein and mRNA expression of PPARγ, LXRα for 24 and 48 hr, SREBP1 for 48 hr and ABCA1 for 96 hr, as well as decreased cellular total cholesterol level for 96 hr in a concentration-dependent manner from 2.5 to 10 μM. To further demonstrate the exactly mechanism, we added the specific antagonists of PPARγ (GW9662) and LXRα (GGPP). We found that lycopene (10 μM) + GW9662 (20 μM) or GGPP (20 μM) significantly restored the proliferation of prostate cancer cells to the control level, suppressed lycopene -induced cholesterol efflux, as well as protein and mRNA expression of PPARγ and LXRα. In summary, the present study demonstrates that lycopene inhibits the proliferation of androgen-dependent human prostate cancer LNCaP cells, and the effect is related to the activation of PPARγand LXRα signaling pathway, which then increases the expression of LXRα target genes. | en_US |
dc.description.abstract | 流行病學研究顯示多攝取富含茄紅素的食物能降低多種癌症的發生,包括前列腺癌及肝癌。過氧化體增殖劑活化受體(PPAR)及肝異受體(LXR)的活化會降低前列腺癌的發生。然而其確切抑制前列腺癌細胞的生長機制並不清楚。因此本研究目標即在探討茄紅素在抑制前列腺癌細胞生長中所扮演的調控角色與機制為何。本研究的假說為:茄紅素會經由活化核受體PPARγ與LXRα及其標的基因的表現而抑制男性荷爾蒙依賴型前列腺癌細胞之生長。以茄紅素不同濃度(0, 2.5, 5, 10, 20 μM)分別處理男性荷爾蒙依賴型前列腺癌細胞LNCaP。結果顯示:(1) 茄紅素能抑制LNCaP細胞增生,其效果以10 μM最好;(2) 茄紅素在培養24和48小時能顯著提升LNCaP細胞中PPARγ及LXRα的蛋白與mRNA表現;(3)48小時顯著提升SREBP1的蛋白與mRNA表現;(4)96小時則顯著提升ABCA1的蛋白與mRNA表現,而且顯著降低細胞內膽固醇含量。以上作用均具有濃度效應(2.5-10 μM)。為了更進一步證明茄紅素的確是經由活化PPARγ與LXRα的表現而抑制LNCaP細胞之生長,本研究分別以PPARγ與LXRα的拮抗劑GW9662及GGPP處理LNCaP細胞。結果顯示,茄紅素(10 μM) + GW9662 (20 μM)或GGPP (20 μM)可回復LNCaP細胞生長,並且與控制組相當,同時也降低了PPARγ及LXRα的蛋白與mRNA表現,並且顯著回復茄紅素所抑制的細胞內膽固醇含量。綜合上述結果,我們證實了茄紅素可活化PPARγ及LXRα的訊息傳遞,使其標的基因表現增加,以及減少細胞內膽固醇含量,增加膽固醇輸出,而抑制男性荷爾蒙依賴型前列腺癌細胞的生長。 | zh_TW |
dc.description.tableofcontents | 縮寫表……………………………………………………………………I 中文摘要…………………………………………………………………II 英文摘要………………………………………………………………XIII 文獻整理…………………………………………………………………1 1. 前列腺癌………………………………………………………………1 2. 茄紅素…………………………………………………………………1 2.1 簡介…………………………………………………………………1 2.2 結構…………………………………………………………………2 2.3 茄紅素的生理功能…………………………………………………2 2.4 茄紅素的抗癌機制…………………………………………………3 2.5 茄紅素與前列腺癌…………………………………………………5 3. 核受體(nuclear receptors)………………………………………6 3.1過氧化體增殖劑活化受體(Peroxisome proliferators-activated receptor, PPAR)……………………………………………7 3.2肝異受體(Liver X receptor, LXR)………………………………9 3.3 膽固醇代謝與脂質合成基因(LXRα標的基因)…………………12 4. 膽固醇與前列腺癌…………………………………………………13 研究動機…………………………………………………………………15 研究目的與假說…………………………………………………………16 實驗架構…………………………………………………………………17 材料與方法………………………………………………………………18 實驗材料…………………………………………………………………18 1. 實驗藥品……………………………………………………………18 2. 其他材料……………………………………………………………21 3. 儀器設備……………………………………………………………21 實驗方法………………………………………………………………22 1. 茄紅素製備…………………………………………………………22 2. 細胞解凍……………………………………………………………22 3. 細胞保存……………………………………………………………23 4. 細胞培養……………………………………………………………23 5. 細胞增生實驗………………………………………………………23 6. Western blotting…………………………………………………23 7. 總RNA萃取……………………………………………………………27 8. 反轉錄作用…………………………………………………………28 9. 聚合酶連鎖反應(PCR)………………………………………………29 10. DNA電泳……………………………………………………………29 11. 總膽固醇之測定……………………………………………………30 12. 統計分析……………………………………………………………31 結果………………………………………………………………………32 1. 茄紅素對前列腺癌細胞LNCaP增生之影響…………………………32 2. 茄紅素對前列腺癌LNCaP細胞中PPARγ、LXRα、ABCA1 、SREBP1及apoA-I蛋白質與mRNA表現之影響……………………32 3. 茄紅素對前列腺癌細胞LNCaP的細胞內膽固醇含量之影響………40 4. PPARγ、LXRα拮抗劑對茄紅素作用前列腺癌細胞LNCaP 增生之影響………………………………………………………………40 5. PPARγ、LXRα拮抗劑對茄紅素作用前列腺癌LNCaP細胞 中PPARγ及LXRα蛋白質與mRNA表現之影響…………………………40 6. PPARγ、LXRα拮抗劑對茄紅素作用前列腺癌細胞LNCaP 的細胞內膽固醇含量之影響……………………………………………42 7. 單獨使用PPARγ、LXRα拮抗劑對前列腺癌LNCaP細胞增生及細胞中PPARγ及LXRα蛋白質表現之影響…………………………………42 討論………………………………………………………………………44 結論………………………………………………………………………49 圖表………………………………………………………………………50 參考文獻…………………………………………………………………95 附錄……………………………………………………………………109 | zh_TW |
dc.language.iso | en_US | zh_TW |
dc.publisher | 食品暨應用生物科技學系所 | zh_TW |
dc.subject | Lycopene | en_US |
dc.subject | 茄紅素 | zh_TW |
dc.subject | prostate cancer | en_US |
dc.subject | PPARγ | en_US |
dc.subject | LXRα | en_US |
dc.subject | 前列腺癌 | zh_TW |
dc.subject | 過氧化體增殖劑活化受體 | zh_TW |
dc.subject | 肝異受體 | zh_TW |
dc.title | Lycopene inhibits the proliferation of androgen-dependent human prostate LNCaP tumor cells through activation of PPARγ and LXRα signaling pathway | en_US |
dc.title | 茄紅素活化核受體PPARγ與LXRα訊息傳遞路徑而抑制男性荷爾蒙依賴型前列腺癌LNCaP細胞之增生 | zh_TW |
dc.type | Thesis and Dissertation | zh_TW |
item.openairetype | Thesis and Dissertation | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en_US | - |
item.grantfulltext | none | - |
item.fulltext | no fulltext | - |
item.cerifentitytype | Publications | - |
Appears in Collections: | 食品暨應用生物科技學系 |
TAIR Related Article
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.